Joost L. Boormans

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

Roland Seiler, H.A.D.M. Ashab, Nicholas Erho et al. · European Urology · 2017 · 792 citations

Medicine, Oncology, Urology +13

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni et al. · The Lancet Oncology · 2021 · 533 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

J. Alfred Witjes, Marek Babjuk, Joaquim Bellmunt et al. · European Urology · 2019 · 192 citations · Full text

Medicine, Oncology, Urology +16

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Alan Horwich, Marek Babjuk, Joaquim Bellmunt et al. · Annals of Oncology · 2019 · 182 citations · Full text

Medicine, Oncology, Urology +17

Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer

Andrea Necchi, Daniele Raggi, Andrea Gallina et al. · European Urology · 2020 · 178 citations

Medicine, Immunology, Oncology +17